A. Jakubowiak

发表

Initial genome sequencing and analysis of multiple myeloma

Trevor J Pugh, A. Sivachenko, K. Cibulskis, 2011, Nature.

A phase 1 dose‐escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma

J. Fay, B. Tunquist, A. Jakubowiak, 2016, Cancer.

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

K. Anderson, C. Hofmeister, S. Jagannath, 2014, Blood.

A randomized open-label study of bortezomib, melphalan, and prednisone (VMP) versus daratumumab (DARA) plus VMP in patients with previously untreated multiple myeloma (MM) who are ineligible for high-dose therapy: 54767414MMY3007 (Alcyone).

A. Jakubowiak, J. Miguel, W. Crist, 2015 .

Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition

S. Varambally, A. Chinnaiyan, A. Jakubowiak, 2007, Proceedings of the National Academy of Sciences.

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

H. Einsele, S. Jagannath, A. Jakubowiak, 2022, Blood Cancer Journal.

International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

G. Morgan, A. Jakubowiak, A. Krishnan, 2020, Leukemia.

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.

Michael L. Wang, A. Hui, A. Jakubowiak, 2014, Blood.

Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/ Refractory Multiple Myeloma

A. Jakubowiak, Shaji K. Kumar, E. Ocio, 2013 .

Study of the dynamics of sertoli cell secretions in a new superfusion, two-compartment culture system

A. Jakubowiak, A. Steinberger, A. Janecki, 1987, In Vitro Cellular & Developmental Biology.

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

Andre H Crepaldi, M. Dimopoulos, A. Jakubowiak, 2017, The New England journal of medicine.

Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib‐based treatment regimens

A. Nesvizhskii, A. Jakubowiak, P. Richardson, 2015, British journal of haematology.

Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study

K. Anderson, A. Jakubowiak, T. Zimmerman, 2012, British journal of haematology.

Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

J. Shah, S. Jagannath, A. Jakubowiak, 2019, Blood.

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

A. Jakubowiak, Wan-Jen Hong, Shaji K. Kumar, 2018, Blood advances.

Knowing the unknowns in high risk multiple myeloma.

A. Jakubowiak, B. Derman, S. Kosuri, 2021, Blood reviews.

Current approaches to the initial treatment of symptomatic multiple myeloma.

A. Jakubowiak, J. Jasielec, 2013, International journal of hematologic oncology.

Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia.

M. Kaminski, A. Jakubowiak, P. Ouillette, 2007, Blood.

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

M. Dimopoulos, A. Palumbo, A. Jakubowiak, 2017, British journal of haematology.

Oprozomib in patients with newly diagnosed multiple myeloma

P. Sonneveld, A. Jakubowiak, P. Hari, 2019, Blood Cancer Journal.

M. Dimopoulos, A. Palumbo, A. Jakubowiak, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies

A. Jakubowiak, H. Kindler, T. Gajewski, 2022, Journal for ImmunoTherapy of Cancer.

Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies

A. Jakubowiak, G. Cavaletti, 2010, Leukemia & lymphoma.

Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients.

P. Riedell, Sonali M. Smith, A. Jakubowiak, 2020, Journal of geriatric oncology.

Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults.

P. Riedell, A. Jakubowiak, R. Larson, 2019, Blood advances.

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.

C. Hofmeister, A. Jakubowiak, T. Zimmerman, 2016, Blood.

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

Michael L. Wang, M. Dimopoulos, A. Palumbo, 2016, Blood.

Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma

M. Kaminski, K. Griffith, S. Jagannath, 2014, Haematologica.

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2013, Leukemia.

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment

A. Palumbo, A. Jakubowiak, D. Siegel, 2017, Blood cancer journal.

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.

A. Jakubowiak, R. Vij, N. Munshi, 2011, The Lancet. Oncology.

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2007 .

Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2007 .

Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma

A. Jakubowiak, Shaji K. Kumar, P. Mavros, 2022, The oncologist.

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma

D. Auclair, R. Fonseca, S. Jagannath, 2017, Clinical lymphoma, myeloma & leukemia.

Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies

A. Jakubowiak, J. DeCara, Khalid Mezzi, 2017, Hematology.

Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib.

K. Anderson, A. Jakubowiak, A. Krishnan, 2007 .

Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma

Shenmin Zhang, A. Jakubowiak, Zuxun Zhang, 2022, Journal of Hematology & Oncology.

The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1

A. Jakubowiak, S. Nimer, R. Frank, 1999, Oncogene.

Transferrin secretion in response to different modes of FSH stimulation and cycloheximide in superfused Sertoli cell cultures.

A. Jakubowiak, A. Steinberger, A. Janecki, 1988, Journal of andrology.

Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study

A. Jakubowiak, T. Zimmerman, M. Bishop, 2020, Journal for ImmunoTherapy of Cancer.

Phase 2 study of venetoclax plus car ﬁ lzomib and dexamethasone in patients with relapsed/refractory multiple myeloma

A. Jakubowiak, Wan-Jen Hong, Shaji K. Kumar, 2021 .

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

Andre H Crepaldi, M. Dimopoulos, A. Jakubowiak, 2019, The Lancet.

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

S. Jagannath, A. Jakubowiak, N. Munshi, 2021, The Lancet.

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

M. Dimopoulos, A. Jakubowiak, Shaji K. Kumar, 2022, Blood.

Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.

A. Jakubowiak, A. Krishnan, S. Lonial, 2021, Clinical lymphoma, myeloma & leukemia.

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.

K. Griffith, A. Jakubowiak, R. Vij, 2020, Blood.

Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN.

A. Jakubowiak, J. Laubach, P. Richardson, 2020, Blood.

Daratumumab Plus Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

A. Jakubowiak, S. Lonial, A. Oriol, 2019, Blood.

S. Jagannath, A. Jakubowiak, P. Hari, 2022, The Lancet. Haematology.

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2014, Blood.

patients with newly diagnosed multiple myeloma Lenalidomide, bortezomib, and dexamethasone combination therapy in

D. Esseltine, S. Jagannath, A. Jakubowiak, 2012 .

Selinexor‐based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy

S. Jagannath, A. Jakubowiak, A. Chari, 2020, British journal of haematology.

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

A. Jakubowiak, T. Zimmerman, T. Karrison, 2019, British journal of haematology.

Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study

G. Ahmann, R. Fonseca, S. Jagannath, 2016 .

Reproductive functions in the adult male rats after prolonged intraventricular administration of corticotropin-releasing factor (CRF).

A. Jakubowiak, B. Miśkowiak, A. Janecki, 2009, Experimental and clinical endocrinology.

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.

G. Ahmann, R. Fonseca, S. Jagannath, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 Dose-Escalation Study of MLN4924, a Novel NAE Inhibitor, in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.

G. Mulligan, A. Jakubowiak, S. Lonial, 2009 .

Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma

Matthew J. Frigault, A. Jakubowiak, S. Nikiforow, 2022, Blood advances.

Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies

A. Jakubowiak, O. Landgren, M. Roussel, 2019, Leukemia & lymphoma.

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

S. Jagannath, A. Jakubowiak, S. Lonial, 2015, The Lancet. Haematology.

Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial

M. Kaminski, D. Esseltine, K. Griffith, 2009 .

High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2009 .

High Rate of Complete and near Complete Responses (CR/nCR) after Initial Therapy with Bortezomib (Velcade®), Doxil®, and Dexamethasone (VDD) Is Further Increased after Autologous Stem Cell Transplantation (ASCT).

M. Kaminski, A. Jakubowiak, S. Mineishi, 2006 .

A phase 2 study of single-agent carﬁlzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Evolving strategies in the initial treatment of multiple myeloma.

A. Jakubowiak, J. Laubach, P. Richardson, 2013, Seminars in oncology.

Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)

K. Griffith, S. Jagannath, A. Jakubowiak, 2011 .

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.

M. Kaminski, D. Esseltine, K. Griffith, 2011, Blood.

Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM).

K. Anderson, A. Jakubowiak, A. Krishnan, 2006 .

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2015, Leukemia & lymphoma.

Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.

A. Jakubowiak, 2014, Cancer treatment reviews.

Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis

S. Jagannath, A. Jakubowiak, S. Lonial, 2011 .

Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.

S. Jagannath, A. Jakubowiak, S. Lonial, 2009 .

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

H. Goldschmidt, M. Dimopoulos, A. Jakubowiak, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma

A. Jakubowiak, B. Chiu, B. Derman, 2022, Cancers.

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.

F. Aguet, L. Trippa, A. Jakubowiak, 2022, Cancer cell.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia

A. Jakubowiak, D. Siegel, R. Vij, 2019, Clinical Cancer Research.

Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM).

S. Jagannath, A. Jakubowiak, D. Siegel, 2016, Journal of Clinical Oncology.

Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.

S. Jagannath, A. Jakubowiak, P. Hari, 2022, Clinical lymphoma, myeloma & leukemia.

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

S. Jagannath, A. Jakubowiak, N. Munshi, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of cyclic AMP and phorbol ester on transepithelial electrical resistance of Sertoli cell monolayers in two-compartment culture

A. Jakubowiak, A. Steinberger, A. Janecki, 1991, Molecular and Cellular Endocrinology.

Stimulatory effect of Sertoli cell secretory products on testosterone secretion by purified Leydig cells in primary culture

A. Jakubowiak, A. Janecki, A. Lukaszyk, 1985, Molecular and Cellular Endocrinology.

Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States

A. Jakubowiak, M. Campioni, Á. Benedict, 2017, Expert review of hematology.

Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, S. Lonial, 2014 .

Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN

A. Jakubowiak, J. Laubach, P. Richardson, 2019, Clinical Lymphoma Myeloma and Leukemia.

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

D. Auclair, A. Jakubowiak, J. Laubach, 2018, Blood.

Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study.

A. Jakubowiak, S. Lonial, A. Chari, 2017 .

Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)

K. Griffith, A. Jakubowiak, R. Vij, 2016 .

Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).

A. Jakubowiak, R. Vij, A. Belch, 2009 .

Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor

A. Jakubowiak, A. Mayampurath, S. Volchenboum, 2015, Molecular Cancer Therapeutics.

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

S. Jagannath, A. Jakubowiak, S. Lonial, 2012, Clinical lymphoma, myeloma & leukemia.

Printed in U.S.A. Copyright © 1997 by The Endocrine Society Differential Effects of Gonadotropin-Releasing Hormone (GnRH) Pulse Frequency on Gonadotropin Subunit and GnRH Receptor Messenger Ribonucleic Acid Levels in Vitro*

A. Jakubowiak, U. Kaiser, W. Chin, 2022 .

Regulation of rat pituitary gonadotropin-releasing hormone receptor mRNA levels in vivo and in vitro.

A. Jakubowiak, U. Kaiser, W. Chin, 1993, Endocrinology.

Evaluation of HLA Expression on Gametogenic Cells Isolated from Human Testis/Auswertung der HLA‐Expression von Keimzellen aus dem menschlichen Hoden

A. Jakubowiak, M. Kurpisz, G. Szymczyński, 2009, Andrologia.

Kinetics of inhibin secretion in static and superfused Sertoli cell cultures in response to follicle-stimulating hormone.

A. Jakubowiak, A. Steinberger, A. Janecki, 1990, Biology of reproduction.

Vectorial secretion of inhibin by immature rat Sertoli cells in vitro: reexamination of previous results.

A. Jakubowiak, A. Steinberger, A. Janecki, 1990, Endocrinology.

Regulation of transepithelial electrical resistance in two-compartment Sertoli cell cultures: in vitro model of the blood-testis barrier.

A. Jakubowiak, A. Steinberger, A. Janecki, 1991, Endocrinology.

Current strategies for treatment of relapsed/refractory multiple myeloma

A. Jakubowiak, S. Lonial, J. Laubach, 2014, Expert review of hematology.

Effects of recombinant human inhibin and testosterone on gonadotropin secretion and subunit mRNA in superfused male rat pituitary cell cultures stimulated with pulsatile gonadotropin-releasing hormone

A. Jakubowiak, A. Steinberger, B. Sanborn, 1991, Molecular and Cellular Endocrinology.

A. Jakubowiak, A. Steinberger, A. Janecki, 1989, Biology of reproduction.

Potent anti‐myeloma activity of the TOPK inhibitor OTS514 in pre‐clinical models

David W. Johnson, Yusuke Nakamura, A. Jakubowiak, 2019, Cancer medicine.

Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective

A. Jakubowiak, M. Campioni, Á. Benedict, 2016, Journal of medical economics.

Effect of cadmium chloride on transepithelial electrical resistance of Sertoli cell monolayers in two-compartment cultures--a new model for toxicological investigations of the "blood-testis" barrier in vitro.

A. Jakubowiak, A. Steinberger, A. Janecki, 1992, Toxicology and applied pharmacology.

Molecular biology of leukemia

A. Jakubowiak, C. Hedvat, S. Nimer, 2000, Current oncology reports.

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Michael L. Wang, M. Dimopoulos, A. Palumbo, 2015, The New England journal of medicine.

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy

A. Jakubowiak, J. Laubach, P. Richardson, 2020 .

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma

P. Sonneveld, A. Jakubowiak, D. Siegel, 2019, Leukemia.

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

M. Kaminski, K. Griffith, S. Jagannath, 2012, Blood.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2010, Blood.

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

A. Chinnaiyan, D. Auclair, P. L. Bergsagel, 2022, Nature Communications.

Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).

J. Crowley, B. Barlogie, A. Jakubowiak, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah’s Witnesses

P. Riedell, Sonali M. Smith, A. Jakubowiak, 2021, Leukemia and Lymphoma.

Cladribine Underdosing in Hairy-cell Leukemia: a Cause for Apparent Response Failure

A. Jakubowiak, D. Golde, M. Heaney, 2002, Leukemia & lymphoma.

Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, N. Munshi, 2021, Blood.

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin

A. Jakubowiak, Sharmila Patel, J. Laubach, 2021, Blood.

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance

A. Jakubowiak, Sharmila Patel, J. Laubach, 2021, Blood.

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

H. Goldschmidt, M. Dimopoulos, A. Jakubowiak, 2020, Blood Cancer Journal.

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

G. Mulligan, S. Tirrell, A. Jakubowiak, 2015, Clinical Cancer Research.

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

A. Jakubowiak, A. Krishnan, S. Lonial, 2016, The Lancet.

Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells

A. Jakubowiak, A. Mitra, B. V. Van Ness, 2017, Oncotarget.

Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice

H. Einsele, S. Jagannath, A. Jakubowiak, 2022, Haematologica.

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Anthony Boral, Hartmut Goldschmidt, Mario Boccadoro, 2007, Blood.

Novel therapies for relapsed/refractory multiple myeloma: how can we improve on "salvage" therapy?--introduction.

A. Jakubowiak, 2012, Seminars in hematology.

Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives.

A. Jakubowiak, 2012, Seminars in hematology.

First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

A. Jakubowiak, R. Vij, J. Sheridan, 2020, Clinical Cancer Research.

Daratumumab (DARA) Plus Carfilzomib, Pomalidomide, Dexamethasone (KPd) in Lenalidomide Refractory Multiple Myeloma (MM): A Multi-Center MMRC Study

Megan F. Whelan, K. Griffith, A. Jakubowiak, 2020 .

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study.

K. Griffith, A. Jakubowiak, T. Zimmerman, 2016 .

Monoclonal antibodies in the treatment of multiple myeloma

A. Jakubowiak, S. Lonial, P. Richardson, 2011, British journal of haematology.

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone

Andre H Crepaldi, M. Dimopoulos, A. Jakubowiak, 2019, Blood.

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

D. Esseltine, P. Sonneveld, A. Jakubowiak, 2008, British journal of haematology.

Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells

A. Jakubowiak, S. Chung, Y. Nakamura, 2016, Blood Cancer Journal.

Andre H Crepaldi, M. Dimopoulos, A. Jakubowiak, 2021, BMC cancer.

Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

A. Jakubowiak, S. Trudel, A. Lesokhin, 2020 .

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.

A. Jakubowiak, D. Siegel, T. Zimmerman, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

S. Jagannath, A. Jakubowiak, J. Goldberg, 2019, Blood.

Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

A. Jakubowiak, A. Lesokhin, N. Raje, 2019, Blood.

A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma

A. Jakubowiak, A. Lesokhin, N. Raje, 2018, Blood.

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

A. Jakubowiak, S. Ziyad, Kelvin P Lee, 2018, Blood.

Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.

A. Jakubowiak, A. Krishnan, S. Lonial, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).

A. Jakubowiak, D. Siegel, J. Kaufman, 2020 .

Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, D. Siegel, 2021, Blood.

Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.

S. Jagannath, A. Jakubowiak, J. Goldberg, 2020 .

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.

Michael D. Robbins, A. Jakubowiak, B. Pégourié, 2016, Blood.

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.

K. Griffith, A. Jakubowiak, J. Zaucha, 2023, The Lancet. Oncology.

Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients

F. Zhan, S. Jagannath, A. Jakubowiak, 2011, European journal of haematology.

Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies.

M. Dimopoulos, A. Jakubowiak, J. San-Miguel, 2020, Clinical lymphoma, myeloma & leukemia.

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study

A. Jakubowiak, S. Lonial, J. Kaufman, 2019, Blood Cancer Journal.

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment

A. Palumbo, A. Jakubowiak, R. Hájek, 2017, Blood Cancer Journal.

Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy

A. Jakubowiak, K. Giannopoulos, M. Luczak, 2016, Oncotarget.

An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, British journal of haematology.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carﬁlzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.

M. Kaminski, A. Jakubowiak, S. Mineishi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.

A. Jakubowiak, J. Zonder, T. Karrison, 2022, JAMA oncology.

Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.

A. Jakubowiak, Sharmila Patel, J. Laubach, 2022, Transplantation and cellular therapy.

Multiple Myeloma in Older Adults

A. Jakubowiak, W. Dale, Saleha Sajid, 2014, Current Geriatrics Reports.

Multiple Myeloma : 2007-2008

A. Jakubowiak, S. Lonial, P. Richardson, 2008 .

Moving Toward a Cure in Multiple Myeloma: Eradication of Measurable Residual Disease

A. Jakubowiak, B. Derman, 2022, Advances in Oncology.

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

J. Rossi, S. Jagannath, A. Jakubowiak, 2011 .

Elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: A randomized phase II study.

J. Rossi, S. Jagannath, A. Jakubowiak, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.

M. Dimopoulos, A. Jakubowiak, A. Oriol, 2021, The Lancet. Oncology.

Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study

A. Jakubowiak, A. Krishnan, S. Lonial, 2017 .

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies.

A. Jakubowiak, S. Malek, N. Donato, 2015, Blood.

Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up

D. Esseltine, S. Jagannath, A. Jakubowiak, 2010 .

Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

A. Jakubowiak, S. Lonial, P. Thulasi, 2020, Ophthalmology and Therapy.

Inhibition of the Transforming Growth Factor β1 Signaling Pathway by the AML1/ETO Leukemia-associated Fusion Protein*

A. Jakubowiak, J. Massagué, S. Nimer, 2000, The Journal of Biological Chemistry.

Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

S. Jagannath, A. Jakubowiak, D. Siegel, 2014 .

UPDATED RESULTS FROM THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

S. Jagannath, A. Jakubowiak, P. Hari, 2021, Hematology, Transfusion and Cell Therapy.

Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).

A. Jakubowiak, S. Trudel, M. Tomasson, 2021 .

Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

C. Hofmeister, A. Jakubowiak, T. Zimmerman, 2011 .

Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset

S. Jagannath, A. Jakubowiak, J. Goldberg, 2019, Blood.

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

S. Jagannath, A. Jakubowiak, D. Siegel, 2020 .

Effect of germ cells on vectorial secretion of androgen binding protein and transferrin by immature rat Sertoli cells in vitro.

A. Jakubowiak, A. Steinberger, A. Janecki, 1988, Journal of andrology.

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib

A. Jakubowiak, A. Krishnan, S. Lonial, 2008 .

Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1

A. Jakubowiak, S. Trudel, M. Tomasson, 2021, Blood.

Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, P. Hari, 2020, Transplantation and Cellular Therapy.

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, N. Munshi, 2020 .

S. Jagannath, A. Jakubowiak, P. Hari, 2020, Transplantation and Cellular Therapy.

Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis

A. Jakubowiak, Wei Zhang, B. Chiu, 2020, Blood Cancer Journal.

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)

R. Dana, A. Jakubowiak, S. Lonial, 2021, Blood Cancer Journal.

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

A. Jakubowiak, Shaji K. Kumar, B. Laplant, 2022, Blood.

Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data

A. Jakubowiak, Shaji K. Kumar, B. Laplant, 2020 .

Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study

A. Hui, A. Jakubowiak, S. Lonial, 2011 .

Elotuzumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: 2-Year Follow-up

A. Jakubowiak, B. Pégourié, J. Laubach, 2015 .

Treatments for newly diagnosed multiple myeloma: when endurance is interrupted.

A. Jakubowiak, O. Landgren, D. Kazandjian, 2020, The Lancet Oncology.

Efficacy and Safety of Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis

S. Jagannath, A. Jakubowiak, P. Hari, 2021, Blood.

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM).

C. Hofmeister, A. Jakubowiak, T. Zimmerman, 2009 .

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study

A. Jakubowiak, S. Lonial, J. Kaufman, 2019, Blood Cancer Journal.

Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)

M. Dimopoulos, A. Jakubowiak, Sung-Soo Yoon, 2017 .

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial

H. Goldschmidt, M. Dimopoulos, A. Jakubowiak, 2017 .

Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.

S. Jagannath, A. Jakubowiak, S. Lonial, 2013 .

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

K. Griffith, A. Jakubowiak, R. Vij, 2017 .

Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM).

K. Griffith, A. Jakubowiak, J. Levy, 2015 .

Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE.

M. Dimopoulos, A. Jakubowiak, Shaji K. Kumar, 2021, Blood.

Genomic Basis of Multiple Myeloma Subtypes from the MMRF CoMMpass Study

Winnie S. Liang, J. Carpten, S. Jewell, 2021, medRxiv.

Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.

S. Jagannath, A. Jakubowiak, P. Hari, 2021 .

A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results

S. Jagannath, A. Jakubowiak, S. Lonial, 2012 .

Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study

J. Rossi, S. Jagannath, A. Jakubowiak, 2010 .

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

A. Jakubowiak, S. Trudel, M. Tomasson, 2022, Blood.

Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001.

A. Jakubowiak, S. Lonial, P. Moreau, 2018 .

Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391).

M. Dimopoulos, A. Jakubowiak, D. Siegel, 2016 .

Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.

M. Kaminski, K. Griffith, S. Jagannath, 2013 .

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

S. Jagannath, A. Jakubowiak, R. Vij, 2009 .

Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Studyof Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)

S. Jagannath, A. Jakubowiak, D. Siegel, 2008 .

Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.

K. Anderson, A. Jakubowiak, D. Siegel, 2010 .

The Speed of Response to Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma: An Exploratory Analysis of Results From 2 Multicenter Phase 2 Clinical Trials,

A. Jakubowiak, D. Siegel, R. Vij, 2011 .

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

J. Shah, M. Dimopoulos, C. Hofmeister, 2020, Leukemia.

Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial

K. Griffith, S. Jagannath, A. Jakubowiak, 2010 .

P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN

A. Jakubowiak, J. Laubach, P. Richardson, 2022, HemaSphere.

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2011 .

One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone

M. Dimopoulos, A. Jakubowiak, Sung-Soo Yoon, 2018, Blood.

Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies

A. Jakubowiak, D. Siegel, R. Vij, 2016 .

Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391)

Michael L. Wang, M. Dimopoulos, A. Palumbo, 2015 .

A Phase II Study of Consolidation Treatment with Iodione-131 Tositumomab (Bexxar™) in Multiple Myeloma (MM)

M. Kaminski, K. Griffith, A. Jakubowiak, 2012 .

Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results.

A. Jakubowiak, T. Zimmerman, A. Singhal, 2009 .

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

A. Jakubowiak, Sharmila Patel, P. Richardson, 2022, Blood Cancer Journal.

A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma

A. Jakubowiak, A. Chari, J. Zonder, 2023, European journal of haematology.

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

A. Jakubowiak, J. Laubach, P. Richardson, 2019, Blood.

Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

A. Jakubowiak, A. Stefka, B. Derman, 2021, Blood Cancer Journal.

Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies

A. Jakubowiak, Sharmila Patel, J. Laubach, 2021, Blood.

Daratumumab plus bortezomib-melphalan-prednisone (VMP) in elderly (≥75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE).

A. Jakubowiak, S. Iida, Je-Jung Lee, 2018 .

Combination Therapy with Velcade, Doxil, and Dexamethasone (VDD) for Patients with Relapsed/Refractory Multiple Myeloma (MM).

M. Kaminski, A. Jakubowiak, J. Friedman, 2005 .

Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy.

A. Jakubowiak, M. Joks, M. Komarnicki, 2017, Polish archives of internal medicine.

B480 Proteomic Alterations Caused by Treatment with Velcade, Doxorubicin, and Dexamethasone in Myeloma

A. Nesvizhskii, A. Jakubowiak, A. Sreekumar, 2009 .

Perspectives on Drug Development in Multiple Myeloma—Looking Forward to 2025

A. Jakubowiak, R. Pazdur, Shaji K. Kumar, 2021, Clinical Cancer Research.

Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study.

D. Esseltine, K. Anderson, S. Jagannath, 2010 .

Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma.

A. Jakubowiak, A. Major, B. Derman, 2022, Clinical Lymphoma, Myeloma & Leukemia.

Deubiquitinase Usp9X Regulates Cell Survival and Metabolic Signal Transduction in Multiple Myeloma Cells

A. Jakubowiak, N. Donato, M. Talpaz, 2011 .

Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts)

K. Griffith, A. Jakubowiak, R. Vij, 2014 .

Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).

M. Dimopoulos, A. Jakubowiak, D. Siegel, 2015 .

A268 Phase I/II Trial of Lenalidomide, Bortezomib, Doxil, and Dexamethasone in Front-Line Multiple Myeloma

M. Kaminski, D. Esseltine, K. Griffith, 2009 .

Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib

A. Jakubowiak, R. Vij, N. Munshi, 2010 .

Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Results from the Prospective, Longitudinal, Observational Commpass Study

D. Auclair, A. Jakubowiak, D. Siegel, 2018, Blood.

A Phase 1b Study of Oprozomib with Dexamethasone or Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

A. Jakubowiak, P. Hari, F. Galimi, 2018, Blood.

Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses

A. Jakubowiak, A. Krishnan, S. Lonial, 2020, Advances in Therapy.

A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.

Michael L. Wang, A. Jakubowiak, S. Lonial, 2007, Clinical advances in hematology & oncology : H&O.

Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN.

A. Jakubowiak, Sharmila Patel, J. Laubach, 2022, Journal of Clinical Oncology.

Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study

S. Jagannath, A. Jakubowiak, S. Lonial, 2011 .

A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).

A. Jakubowiak, D. Siegel, P. Moreau, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis.

S. Jagannath, A. Jakubowiak, S. Lonial, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Elimination of CD20-Expressing Cells in Multiple Myeloma by Iodine I-131 Tositumomab (Bexxar®) Correlates with Response to Therapy

M. Kaminski, A. Jakubowiak, S. Mineishi, 2008 .

Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM)

A. Jakubowiak, T. Zimmerman, P. Richardson, 2008 .

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

H. Goldschmidt, M. Dimopoulos, A. Jakubowiak, 2020, Blood Cancer Journal.

Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone

M. Dimopoulos, A. Jakubowiak, Shaji K. Kumar, 2020 .

Sex differences in outcomes in multiple myeloma

A. Jakubowiak, Wei Zhang, B. Chiu, 2020, British journal of haematology.

Carfilzomib (CFZ, Kyprolis®), lenalidomide (LEN, Revlimid®), and dexamethasone (DEX) (KRd) combined with autologous stem cell transplant (ASCT) shows improved efficacy compared with KRd without ASCT in newly diagnosed multiple myeloma (NDMM)

K. Griffith, A. Jakubowiak, R. Vij, 2015 .

CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.

S. Jagannath, A. Jakubowiak, A. Lesokhin, 2023, Journal of Clinical Oncology.

Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).

A. Jakubowiak, J. Ritz, S. Nikiforow, 2023, Journal of Clinical Oncology.

Measurable residual disease in peripheral blood in myeloma: dream or reality

A. Jakubowiak, D. Dytfeld, B. Derman, 2023, Current opinion in oncology.

Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study

H. Einsele, S. Jagannath, A. Jakubowiak, 2021, Blood.

A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

A. Jakubowiak, B. Pégourié, J. Laubach, 2015 .

Usp9x Silencing and Enzyme Inhibition Suppress Myeloma Cell Survival and in Vivo Tumor Growth.

A. Jakubowiak, N. Donato, M. Talpaz, 2012 .

Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)

A. Jakubowiak, S. Lonial, P. Thulasi, 2020 .

A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results.

A. Jakubowiak, T. Zimmerman, P. Richardson, 2007 .

Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.

A. Jakubowiak, S. Lonial, Jeffrey N. Martin, 2007 .

Action kinetics of inhibin in superfused pituitary cells depend on gonadotropin-releasing hormone treatment.

A. Jakubowiak, A. Steinberger, A. Janecki, 1990, Endocrinology.

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.

M. Kaminski, D. Esseltine, K. Griffith, 2011, Blood.

Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma

S. Jagannath, A. Jakubowiak, Stephen Palmer, 2023, Oncology and Therapy.

Conflicts of interest, authorship, and disclosures in industry-related scientific publications.

B. Barlogie, J. Shaughnessy, R. Fonseca, 2010, Mayo Clinic proceedings.

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2014, Blood.

Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies

A. Jakubowiak, G. Cavaletti, 2010, Leukemia & lymphoma.

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.

Michael L. Wang, A. Hui, A. Jakubowiak, 2014, Blood.

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma

K. Griffith, A. Jakubowiak, D. Reece, 2023, Blood advances.

A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma

A. Jakubowiak, D. Siegel, S. Trudel, 2019, Clinical Lymphoma Myeloma and Leukemia.

FSH Actions on Sertoli Cell Secretions in Stationary and Superfused Cultures

A. Jakubowiak, A. Steinberger, A. Janecki, 1992 .

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

A. Jakubowiak, Sharmila Patel, J. Laubach, 2022, Blood.

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial

A. Jakubowiak, S. Trudel, M. Tomasson, 2023, Nature Medicine.

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.

A. Jakubowiak, Sharmila Patel, J. Laubach, 2023, The Lancet. Haematology.

Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study

Andre H Crepaldi, M. Dimopoulos, A. Jakubowiak, 2022, Blood.

Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next generation sequencing (NGS) in bone marrow in multiple myeloma treated on phase II trial of KRd+ASCT.

A. Jakubowiak, A. Stefka, B. Derman, 2020 .

The research mission in myeloma

S. Jagannath, A. Jakubowiak, N. Munshi, 2009, Leukemia.

Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)

A. Jakubowiak, T. Zimmerman, P. Richardson, 2010 .